New Connected Devices Seek to Tackle Drug Noncompliance

Noncompliance with drug regimens continues to be a significant healthcare concern. “Today, 60% of patients fail to comply with their medication regimen,” Sai Shankar, director business development - connected devices for Aptar Pharma, tells MD+DI.   Aptar Pharma believes that turning metered-dose inhalers (MDIs) and dry-powder inhalers (DPIs) into connected devices could have an impact. “This can improve patient engagement and significantly increase dose adherence and improve patient health outcomes, as patients manage their treatments more effectively,” says Shankar. “Connected devices provide objective monitoring and real-time data with digital solutions. This improves patient adherence, which reduces hospitalization events in chronic diseases. Hospitalization reduction decreases costs to payers, creating value in healthcare system.”   Aptar Pharma is partnering with a digital health solution provider to develop a portfolio of connected devices such as MDIs and DPIs. “Aptar Pharma offers drug-delivery devices that can bring in the full connected functionality and integrate them with software solutions that are accessible to patients/consumers,” he says.   The company will be highlighting several technologies at the upcoming CPhI Worldwide on October 24-26, 2017, at Messe Frankfurt, Germany.   “For respiratory, we will be featuring our c-Devices portfolio at CPhI, which includes ou...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Source Type: news

Related Links:

Anuvinder Kaur, Muhammad Suleman Riaz, Shiv K. Singh, Uday Kishore
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Veronica Lazar, Lia-Mara Ditu, Gratiela Gradisteanu Pircalabioru, Irina Gheorghe, Carmen Curutiu, Alina Maria Holban, Ariana Picu, Laura Petcu, Mariana Carmen Chifiriuc
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
This study aims to evaluate the bioequivalence of two capecitabine formulations (150-mg tablet) using healthy male subjects under nonfasting conditions. The study was conducted as an open, randomized, three-period, semi-replicated design with three sequences (RRT, RTR, TRR) with a 1-week washout interval. The subjects were selected for the study after having their health status previously assessed by a clinical evaluation and laboratory tests (biochemical and hematological parameters, and urinalysis). A single capecitabine tablet (150 mg) was given in each occasion. Plasma capecitabine concentrations were analyzed by ...
Source: International Journal of Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research
Authors: Shibata N, Matsumoto K, Kitamura S, Sakashita A, Kizawa Y, Hirata KI Abstract A 67-year-old woman was admitted to our hospital due to an acute onset of consciousness disturbance, aphasia and left hemiplegia. Computed tomography revealed multiple systemic infarctions, including brain, kidney and spleen. Transesophageal echocardiography revealed vegetations attached to the mitral valve leaflets, which was suspected to be the embolic source. Repeated blood cultures were negative, and advanced lung cancer was incidentally revealed by computed tomography. She was then diagnosed with nonbacterial thrombotic endo...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Authors: Kawase S, Matsumoto R, Imai S, Kawaguchi K, Hata Y, Horita N, Shiota Y Abstract We herein report a case of pulmonary hyalinizing granuloma (PHG), which is a rare pulmonary mass. A 69-year-old man with no symptoms presented to our hospital because of the appearance of an abnormal shadow on chest X-ray. Computed tomography revealed a right middle-lobe mass with spicula and infiltration into the upper lobe. Since a bronchofiberscopic examination showed no malignant cells in the specimen, the patient underwent thoracoscopic surgery, which revealed PHG. Spiculation and interlobar infiltration, which comprise th...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Authors: Ishii S, Tamiya A, Taniguchi Y, Tanaka T, Abe Y, Isa SI, Tsuyuguchi K, Suzuki K, Atagi S Abstract Nivolumab has become the standard second-line chemotherapy for non-small cell lung cancer. A 73-year-old man with stage IV non-small cell lung cancer received 6 cycles of chemotherapy with nab-paclitaxel/carboplatin/bevacizumab followed by 11 cycles of nab-paclitaxel/bevacizumab; however, treatment was stopped due to pneumothorax. One year after therapy started, a nodule appeared in the left upper lung and increased in size. Mycobacterium abscessus subsp. massiliense disease was diagnosed by a sputum analysis....
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Authors: Ogusu S, Takahashi K, Hirakawa H, Tanaka M, Komiya K, Nakamura T, Egashira R, Kai K, Takeda Y, Kimura S, Sueoka-Aragane N Abstract A 76-year-old asymptomatic man was found to have a mass in the right lower lung field. Although the presence of a mucinous component in the majority of the tumor was shown by magnetic resonance imaging, the presence of cancer cells was suspected by contrast enhancement on computed tomography (CT) and based on the partial accumulation in the marginal regions of the tumor on fluorodeoxyglucose-positron emission tomography (FDG-PET). A transbronchial lung biopsy was non-diagnostic...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Authors: Sasaki A, Egashira H, Sugimoto H, Seki K, Tsukiyama T, Ichita C, Tokoro S, Takizawa S, Kitagawa I, Teshima S, Kako M Abstract A 69-year-old male patient presented with multiple lung nodules revealed by chest-computed tomography (CT) during a preoperative examination for an appendiceal tumor. The nodule diameters ranged from 2-10 mm without either pleural thickening or effusions. A fluorine-18-labeled fluorodeoxyglucose (18F-FDG)-positron emission tomography (PET)/CT scan showed a high FDG uptake in the appendiceal tumor, but almost normal standardized uptake values in the bilateral lung nodules. A CT-guide...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Authors: Tsuchiya K, Karayama M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Suda T Abstract A 53-year-old man with advanced lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) exon 19 deletion received erlotinib. After 12 months of disease control with erlotinib monotherapy, leptomeningeal metastases (LM) occurred. A cerebrospinal fluid examination demonstrated a pre-existing EGFR exon 19 deletion. Bevacizumab was combined with erlotinib, and the LM improved. After six months of combination therapy, however, the LM was exacerbated. A re-examination of the ...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Authors: Sato M, Matsui A, Shimoyama Y, Omote N, Morise M, Hase T, Tanaka I, Suzuki K, Hasegawa Y Abstract Squamous cell carcinoma (SCC) transformation has been identified as a mechanism of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib, in EGFR-mutated lung cancer. However, whether second- or third-generation TKIs can overcome resistance due to SCC transformation remains unclear. We herein report an EGFR-mutated lung adenocarcinoma undergoing transformation into SCC that exhibited a durable response to afatinib, which is a second-gener...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
More News: Cancer | Cancer & Oncology | Education | Germany Health | Medical Devices | Pharmaceuticals | Respiratory Medicine | Study | University of Minnesota | Workshops